Renal cell carcinoma: Current status and emerging therapies

Cancer Treatment Reviews

Volumn 33, Issue 3, 2007, Pages 299-313

  Nelson, Eric C ^a   Evans, Christopher P ^a   Lara Jr , Primo N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Illinois School of Medicine   (United States)

Author keywords

Bevacizumab; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CARCINOGEN; DENDRITIC CELL VACCINE; DIURETIC AGENT; FLUOROURACIL; GEMCITABINE; INFLIXIMAB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEGESTROL; PARACETAMOL; PEGINTERFERON; PHENACETIN; PLACEBO; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE;

ABSENCE OF SIDE EFFECTS; ANEMIA; ASTHENIA; BIRT HOGG DUBE SYNDROME; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FAMILIAL CANCER; FLU LIKE SYNDROME; FLUID SHIFT; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LEIOMYOMATOSIS; LEUKOPENIA; LIVER FAILURE; LOW DRUG DOSE; LUNG EDEMA; MENTAL HEALTH; METASTASIS POTENTIAL; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEPHRECTOMY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRECANCER; PROGNOSIS; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU DISEASE;

BIOLOGICAL THERAPY; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 34248661866     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.12.005     Document Type: Review

References (154)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Moore L.E., Wilson R.T., and Campleman S.L. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 23 (2005) 240-255
3. Chow W.H., Devesa S.S., Warren J.L., and Fraumeni Jr. J.F. Rising incidence of renal cell cancer in the United States. Jama 281 (1999) 1628-1631
4. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
5. Murai M., and Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol 14 (2004) 229-233
6. Zambrano N.R., Lubensky I.A., Merino M.J., Linehan W.M., and Walther M.M. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162 (1999) 1246-1258
7. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
8. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91 (1994) 9700-9704
9. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
10. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
11. Delahunt B., Eble J.N., McCredie M.R., Bethwaite P.B., Stewart J.H., and Bilous A.M. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32 (2001) 590-595
12. Leroy X., Zini L., Leteurtre E., et al. Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol 15 (2002) 1126-1130
13. Amin R., and Anthony P. Metastatic renal oncocytoma: a case report and review of the literature. Clin Oncol (R Coll Radiol) 11 (1999) 277-279
14. Tokuda N., Naito S., Matsuzaki O., Nagashima Y., Ozono S., and Igarashi T. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 176 (2006) 40-43 [Discussion 43]
15. de Peralta-Venturina M., Moch H., Amin M., et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25 (2001) 275-284
16. Martel C.L., and Lara P.N. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 45 (2003) 177-190
17. Parker A.S., Cerhan J.R., Janney C.A., Lynch C.F., and Cantor K.P. Smoking cessation and renal cell carcinoma. Ann Epidemiol 13 (2003) 245-251
18. Pischon T., Lahmann P.H., Boeing H., et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 118 (2006) 728-738
19. Moyad M.A. Review of potential risk factors for kidney (renal cell) cancer. Semin Urol Oncol 19 (2001) 280-293
20. Kamat A.M., Shock R.P., Naya Y., Rosser C.J., Slaton J.W., and Pisters L.L. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63 (2004) 46-50
21. Yu M.C., Mack T.M., Hanisch R., Cicioni C., and Henderson B.E. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 77 (1986) 351-356
22. Goodman M.T., Morgenstern H., and Wynder E.L. A case-control study of factors affecting the development of renal cell cancer. Am J Epidemiol 124 (1986) 926-941
23. McLaughlin J.K., Lindblad P., Mellemgaard A., et al. International renal-cell cancer study. I. Tobacco use. Int J Cancer 60 (1995) 194-198
24. Dhote R., Thiounn N., Debre B., and Vidal-Trecan G. Risk factors for adult renal cell carcinoma. Urol Clin North Am 31 (2004) 237-247
25. Mahabir S., Leitzmann M.F., Virtanen M.J., et al. Prospective study of alcohol drinking and renal cell cancer risk in a cohort of finnish male smokers. Cancer Epidemiol Biomarkers Prev 14 (2005) 170-175
26. Rashidkhani B., Akesson A., Lindblad P., and Wolk A. Alcohol consumption and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer 117 (2005) 848-853
27. Wolk A., Gridley G., Niwa S., et al. International renal cell cancer study. VII. Role of diet. Int J Cancer 65 (1996) 67-73
28. Yuan J.M., Gago-Dominguez M., Castelao J.E., Hankin J.H., Ross R.K., and Yu M.C. Cruciferous vegetables in relation to renal cell carcinoma. Int J Cancer 77 (1998) 211-216
29. Rashidkhani B., Lindblad P., and Wolk A. Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer 113 (2005) 451-455
30. Weikert S., Boeing H., Pischon T., et al. Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 118 (2006) 3133-3139
31. Denton M.D., Magee C.C., Ovuworie C., et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 61 (2002) 2201-2209
32. Kojima Y., Takahara S., Miyake O., Nonomura N., Morimoto A., and Mori H. Renal cell carcinoma in dialysis patients: a single center experience. Int J Urol 13 (2006) 1045-1048
33. Farivar-Mohseni H., Perlmutter A.E., Wilson S., Shingleton W.B., Bigler S.A., and Fowler Jr. J.E. Renal cell carcinoma and end stage renal disease. J Urol 175 (2006) 2018-2020 [Discussion 2021]
34. Shuin T., Yamasaki I., Tamura K., Okuda H., Furihata M., and Ashida S. von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 36 (2006) 337-343
35. Neumann H.P., Bender B.U., Berger D.P., et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 160 (1998) 1248-1254
36. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
37. Maynard M.A., and Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 24 (2004) 1-13
38. Li F.P., Decker H.J., Zbar B., et al. Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma. Ann Intern Med 118 (1993) 106-111
39. Melendez B., Rodriguez-Perales S., Martinez-Delgado B., et al. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1). Hum Genet 112 (2003) 178-185
40. Valle L., Cascon A., Melchor L., et al. About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t(3;8)(p14.1;q24.23) family. Eur J Hum Genet 13 (2005) 570-578
41. Lendvay T.S., and Marshall F.F. The tuberous sclerosis complex and its highly variable manifestations. J Urol 169 (2003) 1635-1642
42. Roach E.S., Gomez M.R., and Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 13 (1998) 624-628
43. Schmidt L.S., Nickerson M.L., Angeloni D., et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172 (2004) 1256-1261
44. Zbar B., Glenn G., Lubensky I., et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153 (1995) 907-912
45. Nickerson M.L., Warren M.B., Toro J.R., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2 (2002) 157-164
46. Vincent A., Farley M., Chan E., and James W.D. Birt-Hogg-Dube syndrome: a review of the literature and the differential diagnosis of firm facial papules. J Am Acad Dermatol 49 (2003) 698-705
47. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30 (2002) 406-410
48. Alam N.A., Barclay E., Rowan A.J., et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol 141 (2005) 199-206
49. Blay J.Y., Rossi J.F., Wijdenes J., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72 (1997) 424-430
50. Wechsel H.W., Feil G., Lahme S., Zumbragel A., Petri E., and Bichler K.H. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)?. Anticancer Res 19 (1999) 2577-2581
51. Maldazys J.D., and deKernion J.B. Prognostic factors in metastatic renal carcinoma. J Urol 136 (1986) 376-379
52. Oto A., Herts B.R., Remer E.M., and Novick A.C. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. AJR Am J Roentgenol 171 (1998) 1619-1624
53. Heidenreich A., and Ravery V. Preoperative imaging in renal cell cancer. World J Urol 22 (2004) 307-315
54. Kashyap M.K., Kumar A., Emelianenko N., et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10 (2005) 258-294
55. In: Greene F.L. (Ed). AJCC cancer staging handbook. 6th ed. (2002), Lippincott Raven Publishers, Philadelphia (PA)
56. Murphy A.M., Gilbert S.M., Katz A.E., et al. Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int 95 (2005) 27-30
57. Siemer S., Lehmann J., Loch A., et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173 (2005) 33-37
58. Gilbert S.M., Murphy A.M., Katz A.E., et al. Re-evaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology 68 (2006) 287-291
59. Thompson R.H., Cheville J.C., Lohse C.M., et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104 (2005) 53-60
60. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?. J Urol 173 (2005) 918-921
61. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol 174 (2005) 1218-1221
62. Patard J.J., Leray E., Rioux-Leclercq N., et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23 (2005) 2763-2771
63. Rini B.I., and Vogelzang N.J. Prognostic factors in renal carcinoma. Semin Oncol 27 (2000) 213-220
64. Bensalah K., Leray E., Fergelot P., et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175 (2006) 859-863
65. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173 (2005) 1496-1501
66. Robson C.J., Churchill B.M., and Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 101 (1969) 297-301
67. von Knobloch R., Seseke F., Riedmiller H., Grone H.J., Walthers E.M., and Kalble T. Radical nephrectomy for renal cell carcinoma: is adrenalectomy necessary?. Eur Urol 36 (1999) 303-308
68. Tsui K.H., Shvarts O., Barbaric Z., Figlin R., de Kernion J.B., and Belldegrun A. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 163 (2000) 437-441
69. Sawai Y., Kinouchi T., Mano M., et al. Ipsilateral adrenal involvement from renal cell carcinoma: retrospective study of the predictive value of computed tomography. Urology 59 (2002) 28-31
70. Moudouni S.M., En-Nia I., Patard J.J., Manunta A., Guille F., and Lobel B. Real indications for adrenalectomy in renal cell carcinoma. Scand J Urol Nephrol 36 (2002) 273-277
71. Sagalowsky A.I., Kadesky K.T., Ewalt D.M., and Kennedy T.J. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 151 (1994) 1181-1184
72. Portis A.J., Yan Y., Landman J., et al. Long-term follow up after laparoscopic radical nephrectomy. J Urol 167 (2002) 1257-1262
73. Saika T., Ono Y., Hattori R., et al. Long-term outcome of laparoscopic radical nephrectomy for pathologic T1 renal cell carcinoma. Urology 62 (2003) 1018-1023
74. Permpongkosol S., Chan D.Y., Link R.E., et al. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol 174 (2005) 1222-1225
75. Harano M., Eto M., Omoto K., et al. Long-term outcome of hand-assisted laparoscopic radical nephrectomy for localized stage T1/T2 renal-cell carcinoma. J Endourol 19 (2005) 803-807
76. Hollingsworth J.M., Miller D.C., Dunn R.L., Montgomery J.S., and Wolf Jr. J.S. Cost trends for oncological renal surgery: support for a laparoscopic standard of care. J Urol 176 (2006) 1097-1101 [Discussion 1101]
77. Miller D.C., Taub D.A., Dunn R.L., Wei J.T., and Hollenbeck B.K. Laparoscopy for renal cell carcinoma: diffusion versus regionalization?. J Urol 176 (2006) 1102-1106 [Discussion 1106-1107]
78. Hsu T.H., Jeffrey Jr. R.B., Chon C., and Presti Jr. J.C. Laparoscopic radical nephrectomy incorporating intraoperative ultrasonography for renal cell carcinoma with renal vein tumor thrombus. Urology 61 (2003) 1246-1248
79. Disanto V., Pansadoro V., Portoghese F., Scalese G.A., and Romano M. Retroperitoneal laparoscopic radical nephrectomy for renal cell carcinoma with infrahepatic vena caval thrombus. Eur Urol 47 (2005) 352-356
80. Kapoor A., Nguan C., Al-Shaiji T.F., et al. Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. Urology (2006)
81. Shuch B., Lam J.S., and Belldegrun A.S. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 7 (2006) 31-38
82. Sutherland S.E., Resnick M.I., Maclennan G.T., and Goldman H.B. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter?. J Urol 167 (2002) 61-64
83. Carini M., Minervini A., Lapini A., Masieri L., and Serni S. Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: progression and long-term survival. J Urol 175 (2006) 2022-2026 [Discussion 2026]
84. Novick A.C. Laparoscopic and partial nephrectomy. Clin Cancer Res 10 (2004) 6322S-6327S
85. Allaf M.E., Bhayani S.B., Rogers C., et al. Laparoscopic partial nephrectomy: evaluation of long-term oncological outcome. J Urol 172 (2004) 871-873
86. Lapini A., Serni S., Minervini A., Masieri L., and Carini M. Progression and long-term survival after simple enucleation for the elective treatment of renal cell carcinoma: experience in 107 patients. J Urol 174 (2005) 57-60 [Discussion 60]
87. Fergany A.F., Saad I.R., Woo L., and Novick A.C. Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases. J Urol 175 (2006) 1630-1633 [Discussion 1633]
88. Gill I.S., Remer E.M., Hasan W.A., et al. Renal cryoablation: outcome at 3 years. J Urol 173 (2005) 1903-1907
89. Cambio A.J., and Evans C.P. Management approaches to small renal tumours. BJU Int 97 (2006) 456-460
90. Hines-Peralta A., and Goldberg S.N. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 10 (2004) 6328S-6334S
91. Hacker A., Dinter D., Michel M.S., and Alken P. High-intensity focused ultrasound as a treatment option in renal cell carcinoma. Expert Rev Anticancer Ther 5 (2005) 1053-1059
92. Hacker A., Michel M.S., Marlinghaus E., Kohrmann K.U., and Alken P. Extracorporeally induced ablation of renal tissue by high-intensity focused ultrasound. BJU Int 97 (2006) 779-785
93. Levy D.A., Slaton J.W., Swanson D.A., and Dinney C.P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159 (1998) 1163-1167
94. Evans C.P. Follow-up surveillance strategies for genitourinary malignancies. Cancer 94 (2002) 2892-2905
95. Kjaer M., Iversen P., Hvidt V., et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 21 (1987) 285-289
96. Master V.A., Gottschalk A.R., Kane C., and Carroll P.R. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol 174 (2005) 473-477 [Discussion 477]
97. Juusela H., Malmio K., Alfthan O., and Oravisto K.J. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 11 (1977) 277-281
98. Trump D, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma (HR-RCC). Paper presented at American Society of Clinical Oncology; 1996.
99. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 (2001) 425-431
100. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 (2005) 843-846
101. Blachere N.E., Udono H., Janetzki S., Li Z., Heike M., and Srivastava P.K. Heat shock protein vaccines against cancer. J Immunother 14 (1993) 352-356
102. Aalamian M., Fuchs E., Gupta R., and Levey D.L. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Urol Oncol 24 (2006) 425-433
103. Amato R.J. Vaccine therapy for renal cell carcinoma. Rev Urol 5 (2003) 65-71
104. Pfannschmidt J., Hoffmann H., Muley T., Krysa S., Trainer C., and Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74 (2002) 1653-1657
105. Alves A., Adam R., Majno P., et al. Hepatic resection for metastatic renal tumors: is it worthwhile?. Ann Surg Oncol 10 (2003) 705-710
106. Hofmann H.S., Neef H., Krohe K., Andreev P., and Silber R.E. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48 (2005) 77-81 [Discussion 81-72]
107. Van Poppel H., and Baert L. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belg 64 (1996) 11-17
108. Rabets J.C., Kaouk J., Fergany A., Finelli A., Gill I.S., and Novick A.C. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64 (2004) 930-934
109. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
110. Mickisch G.H., Garin A., van Poppel H., de Prijck L., and Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
111. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
112. DiBiase S.J., Valicenti R.K., Schultz D., Xie Y., Gomella L.G., and Corn B.W. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol 158 (1997) 746-749
113. Cannady S.B., Cavanaugh K.A., Lee S.Y., et al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys 58 (2004) 253-258
114. Svedman C., Sandstrom P., Pisa P., et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45 (2006) 870-875
115. Doh L.S., Amato R.J., Paulino A.C., and Teh B.S. Radiation therapy in the management of brain metastases from renal cell carcinoma. Oncology (Williston Park) 20 (2006) 603-613 [Discussion 613, 616, 619-620 passsim]
116. Ning S., Trisler K., Wessels B.W., and Knox S.J. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80 (1997) 2519-2528
117. Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol 27 (2000) 177-186
118. Lilleby W., and Fossa S.D. Chemotherapy in metastatic renal cell cancer. World J Urol 23 (2005) 175-179
119. Rini B.I., Vogelzang N.J., Dumas M.C., Wade III J.L., Taber D.A., and Stadler W.M. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18 (2000) 2419-2426
120. Stadler W.M., Halabi S., Rini B., et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 107 (2006) 1273-1279
121. Nanus D.M., Garino A., Milowsky M.I., Larkin M., and Dutcher J.P. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101 (2004) 1545-1551
122. Fojo A.T., Shen D.W., Mickley L.A., Pastan I., and Gottesman M.M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5 (1987) 1922-1927
123. Warner E., Tobe S.W., Andrulis I.L., Pei Y., Trachtenberg J., and Skorecki K.L. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 18 (1995) 251-256
124. Samuels B.L., Hollis D.R., Rosner G.L., et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res 3 (1997) 1977-1984
125. Gleave M.E., Elhilali M., Fradet Y., et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338 (1998) 1265-1271
126. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) CD001425
127. Rosenberg S.A., Yang J.C., Topalian S.L., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama 271 (1994) 907-913
128. Fyfe G.A., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 14 (1996) 2410-2411
129. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 Suppl 1 (2000) S55-S57
130. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
131. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
132. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
133. Fossa S.D. Interferon in metastatic renal cell carcinoma. Semin Oncol 27 (2000) 187-193
134. Choueiri T.K., Hutson T.E., and Bukowski R.M. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 3 (2003) 823-829
135. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
136. Rubio-Viqueira B., and Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7 (2006) 501-512
137. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
138. Lee L., Sudentas P., Donohue B., et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42 (2005) 213-227
139. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
140. Hudes G.R., Carducci M., Tomczak P., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Journal of Clinical Oncology 24S (2006) [Abstract LBA4]
141. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
142. Borgstrom P., Bourdon M.A., Hillan K.J., Sriramarao P., and Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35 (1998) 1-10
143. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
144. Sosman J.A., Flaherty K.T., Atkins M.B., et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol 24S (2006) [Abstract 3031]
145. Bukowski R., Kabbinavar F., Figlin R., et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol 24S (2006) 4523
146. Maisey N.R., Hall K., Lee C., et al. Infliximab: A phase II trial of the tumour necrosis factor (TNFα) monoclonal antibody in patients with advanced renal cell cancer (RCC). J Clin Oncol 22S (2004) [Abstract 4514]
147. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
148. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
149. Eisen T., Bukowski R.M., Staehler M., et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 24S (2006) [Abstract 4524]
150. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
151. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
152. Motzer R.J., Hutson T.E., Tomczak P., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24S (2006) [Abstract LBA3]
153. De Mulder P.H., Roigas S., Gillessen S., et al. Phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24S (2006) [Abstract 4529]
154. Papac R.J., and Poo-Hwu W.J. Renal cell carcinoma: a paradigm of lanthanic disease. Am J Clin Oncol 22 (1999) 223-231